VolitionRx (VNRX) Insider Trading & Ownership $0.68 +0.09 (+16.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest VolitionRx (NYSEAMERICAN:VNRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage15.40%Number OfInsiders Buying(Last 3 Years)6Amount OfInsider Buying(Last 3 Years)$801,506.94Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$64,424.03 Get VNRX Insider Trade Alerts Want to know when executives and insiders are buying or selling VolitionRx stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VNRX Insider Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now VolitionRx Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/16/2023Cameron John ReynoldsCEOBuy10,000$1.22$12,200.00 6/2/2023Salvatore Thomas ButeraCEOBuy10,000$1.59$15,900.00 2/22/2023Guy Archibald InnesDirectorBuy234,000$1.75$409,500.00 12/19/2022Jacob Vincent MicallefInsiderBuy25,000$2.30$57,500.00 12/19/2022Salvatore Thomas ButeraCEOBuy5,000$2.27$11,350.00 12/16/2022Jacob Vincent MicallefInsiderBuy7,339$1.96$14,384.44 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/16/2022Martin Charles FaulkesDirectorBuy55,000$2.10$115,500.00 12/12/2022Salvatore Thomas ButeraCEOBuy4,350$2.09$9,091.50 12/8/2022Nicholas PlummerInsiderBuy4,800$2.07$9,936.00 11/28/2022Salvatore Thomas ButeraCEOBuy5,000$2.21$11,050.00 9/19/2022Jacob Vincent MicallefInsiderBuy13,000$1.70$22,100.00 8/30/2022Cameron John ReynoldsCEOBuy3,500$1.61$5,635.00 8/26/2022Jacob Vincent MicallefInsiderBuy29,000$1.74$50,460.00 8/22/2022Salvatore Thomas ButeraCEOBuy5,000$1.64$8,200.00 8/2/2022Guy Archibald InnesDirectorBuy12,500$2.00$25,000.00 6/6/2022Jason Bradley Md TerrellInsiderSell14,949$2.47$36,924.03 5/16/2022Guy Archibald InnesDirectorBuy10,000$2.37$23,700.00 4/11/2022Jason Bradley Md TerrellInsiderSell10,000$2.75$27,500.00 (Data available from 1/1/2013 forward) VNRX Insider Trading Activity - Frequently Asked Questions Who is on VolitionRx's Insider Roster? The list of insiders at VolitionRx includes Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Martin Charles Faulkes, Nicholas Plummer, and Salvatore Thomas Butera. Learn more on insiders at VNRX. What percentage of VolitionRx stock is owned by insiders? 15.40% of VolitionRx stock is owned by insiders. Learn more on VNRX's insider holdings. Which VolitionRx insiders have been buying company stock? The following insiders have purchased VNRX shares in the last 24 months: Cameron John Reynolds ($12,200.00), Guy Archibald Innes ($409,500.00), and Salvatore Thomas Butera ($15,900.00). How much insider buying is happening at VolitionRx? Insiders have purchased a total of 254,000 VNRX shares in the last 24 months for a total of $437,600.00 bought. VolitionRx Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Compensation: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Compensation: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Compensation: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Compensation: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Compensation: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Compensation: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies FitLife Brands Insider Selling Seres Therapeutics Insider Selling Adaptimmune Therapeutics Insider Selling Black Diamond Therapeutics Insider Selling Puma Biotechnology Insider Selling Galectin Therapeutics Insider Selling Elutia Insider Selling Monopar Therapeutics Insider Selling Atossa Therapeutics Insider Selling Applied Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NYSEAMERICAN:VNRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.